Novobiocin modulates colchicine sensitivity in parental and multidrug-resistant B16 melanoma cells

J Cancer Res Clin Oncol. 1994;120(10):599-604. doi: 10.1007/BF01212814.

Abstract

The effect of the antibiotic agent novobiocin on the sensitivity of melanoma cells to colchicine and vinblastine was examined in drug-sensitive and drug-resistant B16 melanoma cells. A cell line COL/R was selected for colchicine resistance. The COL/R cell line (resistant to 80 ng/ml colchicine) was found to possess the multidrug-resistant (MDR) phenotype. The cells were shown to be cross-resistant to vinblastine and Adriamycin and to overexpress P glycoprotein. P glycoprotein activity was assessed by using the rhodamine 123 accumulation test. Rhodamine accumulation was markedly decreased in COL/R cells as compared to the parental B16 cells. Verapamil reversed drug resistance and increased rhodamine accumulation in COL/R cells. Novobiocin in combination with colchicine or vinblastine synergistically inhibited the proliferation of parental B16 cells. In COL/R cells, novobiocin markedly decreased colchicine resistance and increased rhodamine accumulation. These data show that novobiocin increases the sensitivity of both parental and MDR melanoma cells to microtubule-disrupting cytotoxic drugs.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antimetabolites, Antineoplastic / metabolism
  • Cell Division / drug effects
  • Cell Line
  • Clone Cells
  • Colchicine / toxicity*
  • Dose-Response Relationship, Drug
  • Drug Resistance, Multiple*
  • Melanoma, Experimental
  • Mice
  • Novobiocin / pharmacology*
  • Phenotype
  • Rhodamine 123
  • Rhodamines / metabolism
  • Tumor Cells, Cultured
  • Verapamil / pharmacology
  • Vinblastine / toxicity*

Substances

  • Antimetabolites, Antineoplastic
  • Rhodamines
  • Novobiocin
  • Rhodamine 123
  • Vinblastine
  • Verapamil
  • Colchicine